摘要
阿尔茨海默病(阿尔茨海默病)是一种最常见的神经退行性疾病,其特征是海马和大脑皮质中淀粉样-β(Aβ)肽的聚集。炎症被认为是AD的认知功能下降的发展驱动力的炎症反应过程中,激活的星形胶质细胞和小胶质细胞诱导的Aβ肽产生促炎因子和毒素,促进AD脑部神经退行性疾病、老年痴呆症。因此,抑制胶质细胞过度激活在广告大脑可能会导致治疗效果。雷公藤甲素,从中药雷公藤中提取的一种天然化合物,具有抗炎作用。雷公藤内酯醇对AD样是否具有通过抗炎作用病理的预防作用尚不清楚。目前的研究表明,腹腔注射雷公藤甲素(20μg/kg)15周显著减轻学习和记忆缺陷问题,并在AD转基因小鼠脑阻止Aβ积累(APP/PS1小鼠)。这些结果都伴随着对APP/PS1小鼠雷公藤内酯醇相比APP/PS1小鼠生理盐水治疗脑胶质细胞的激活和炎症因子含量减少。此外,我们观察到有丝分裂原活化蛋白激酶(MAPK p38、ERK和JNK)磷酸化也在APP/PS1小鼠大脑中的雷公藤甲素治疗抑制。总之,我们的研究表明,分子机制研究雷公藤甲素对AD模型的治疗作用可能是通过抑制蛋白激酶活性的抑制炎症反应。
关键词: 阿尔茨海默病、ERK、JNK、p38、炎症、雷公藤内酯醇。
Current Alzheimer Research
Title:Triptolide Rescues Spatial Memory Deficits and Amyloid-β Aggregation Accompanied by Inhibition of Inflammatory Responses and MAPKs Activity in APP/PS1 Transgenic Mice
Volume: 13 Issue: 3
Author(s): Yan-Qiu Cui, Qi Wang, Dong-Mei Zhang, Jun-Ya Wang, Bing Xiao, Yan Zheng, Xiao-Min Wang
Affiliation:
关键词: 阿尔茨海默病、ERK、JNK、p38、炎症、雷公藤内酯醇。
摘要: Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease characterized by aggregation of amyloid-β (Aβ) peptide in the hippocampus and cortex of brain. Neuroinflammation is considered a driving force of the progression of cognitive decline in AD. During the neuroinflammatory process, activated astrocytes and microglia induced by Aβ peptide produce pro-inflammatory factors and neurotoxins, which promote neurodegeneration in AD brain, eventually dementia. Thus, the suppression of glial over-activation in AD brain might result in therapeutic effect. Triptolide, a natural compound extracted from the Chinese medicinal herb Tripterygium wilfordii Hook F., has shown anti-inflammatory effects. Whether triptolide exhibits preventive effects on AD-like pathology via anti-inflammatory action is unclear. The present study showed that intraperitoneal injection of triptolide (20 μg/kg) for 15 weeks markedly alleviated deficits in learning and memory, and prevented Aβ accumulation in the brain of AD transgenic mice (APP/PS1 mice). These results were accompanied by reduction in glial activation and contents of pro-inflammatory factors in the brain of APP/PS1 mice treated by triptolide compared to saline-treated APP/PS1 mice. In addition, we observed that the Mitogen-activated protein kinases (MAPKs, including p38, ERK and JNK) phosphorylation was also suppressed by treatment of triptolide in the brain of APP/PS1 mice. Taken together, our study suggests that molecular mechanisms underlying the therapeutic effects of triptolide on the AD model might involve inhibition of the neuroinflammation by suppressing MAPKs activity.
Export Options
About this article
Cite this article as:
Yan-Qiu Cui, Qi Wang, Dong-Mei Zhang, Jun-Ya Wang, Bing Xiao, Yan Zheng, Xiao-Min Wang , Triptolide Rescues Spatial Memory Deficits and Amyloid-β Aggregation Accompanied by Inhibition of Inflammatory Responses and MAPKs Activity in APP/PS1 Transgenic Mice, Current Alzheimer Research 2016; 13 (3) . https://dx.doi.org/10.2174/156720501303160217122803
DOI https://dx.doi.org/10.2174/156720501303160217122803 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neural Stem Cells Transplanted in a Mouse Model of Parkinson’s Disease Differentiate to Neuronal Phenotypes and Reduce Rotational Deficit
CNS & Neurological Disorders - Drug Targets NMDA Receptors are not Alone: Dynamic Regulation of NMDA Receptor Structure and Function by Neuregulins and Transient Cholesterol-Rich Membrane Domains Leads to Disease-Specific Nuances of Glutamate- Signalling
Current Topics in Medicinal Chemistry NMDA Neurotransmission Dysfunction in Mild Cognitive Impairment and Alzheimers Disease
Current Pharmaceutical Design Nicotinamide and its Pharmacological Properties for Clinical Therapy
Drug Design Reviews - Online (Discontinued) Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Spinal Cord Ischemia/Injury
Current Pharmaceutical Design Pain Alleviation in Anti-Inflammatory and Anti-Allergic Conditions
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Topical Capsaicin for the Treatment of Neuropathic Pain
Current Drug Metabolism Current Management and Treatment of Cerebral Vasospasm Complicating SAH
CNS & Neurological Disorders - Drug Targets Mitophagy: A Novel Therapeutic Target for Treating DN
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Neuropharmacology Modern Approaches to Tissue Engineering of the Spinal Cord: Analytical Review
Current Regenerative Medicine (Discontinued) Erythropoietin: New Horizon in Cardiovascular Medicine
Recent Patents on Cardiovascular Drug Discovery HCN Pacemaker Channels and Pain: A Drug Discovery Perspective
Current Pharmaceutical Design Pathophysiology of Blood-Brain Barrier in Brain Injury in Cold and Hot Environments: Novel Drug Targets for Neuroprotection
CNS & Neurological Disorders - Drug Targets Recent Advances in Biological Strategies for Targeted Drug Delivery
Cardiovascular & Hematological Disorders-Drug Targets Recent Patents in Cartilage Regeneration
Recent Patents on Regenerative Medicine Patents on Technologies of Human Tissue and Organ Regeneration from Pluripotent Human Embryonic Stem Cells
Recent Patents on Regenerative Medicine Role of Methylene Blue in Trauma Neuroprotection and Neuropsychiatric Diseases
CNS & Neurological Disorders - Drug Targets Toxins Targeting Voltage-Activated Ca<sup>2+</sup> Channels and their Potential Biomedical Applications
Current Topics in Medicinal Chemistry